The future of GLP-1 drugs remains uncertain, with market predictions ranging widely. While one perspective suggests that Novo Nordisk stumbled upon success, the conversation highlights Eli Lilly as a potentially stronger innovator in the space. As the market evolves, the focus will be on which company can consistently deliver groundbreaking products.
